Sun, Apr 20, 2014, 12:49 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

  • happycamper5804 happycamper5804 Sep 11, 2012 7:56 AM Flag

    Brean Murray Carret & Co. Starts IntelliPharmaCeutics International (IPCI) at Buy

    Brean Murray Carret & Co. initiates coverage on IntelliPharmaCeutics International (NASDAQ: IPCI) with a Buy. PT $7.00.

    Brean analyst said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista’s potential market timing."

    For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.

    Shares of IntelliPharmaCeutics International closed at $2.86 yesterday, with a 52 week range of $2.40-$3.82.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • FDA = $7-$10

      Sentiment: Strong Buy

    • FDA = $7

      Sentiment: Strong Buy

    • With more stock printing coming (see the IPCI website Investor Relations / Press releases November 25, 2011) to the tune of 30 MILLION $$$ worth the stock will give share holders a Nasty Christmas present of DILUTION !!! But some Mindless Pumpers here like to over look such minor annoyances & believe NO SALES / NO PROFITS for 14 years of business is just great !!! I have a different view & I encourage all new potential investors to do some homework on this before putting a single penny in stock !!! You will thank me for the alert !!! If you like HYPE / Speculation with no action then this stock might just be for you !!!

      Sentiment: Strong Sell

    • $$$$$$$$$$$$$$$$$$$$$$$$$

      Sentiment: Strong Buy

    • $$$$$$$$$$$$$$$$$$$$$$$$

      Sentiment: Strong Buy

    • Press Release: BioMedReports – 8 hours ago , By M.E. Garza

      Shares of Intellipharmaceutics International Inc. (IPCI) ( I) have just risen above both the 50 and 200 day moving averages as investors take note and positions ahead of an important FDA catalyst.

      There have been some false starts ahead of the firm`s first, and long awaited, regulatory approval in the past, but as we told our premium subscribers last week, Brean Murray, Carret & Co.- the full-service, boutique investment bank dedicated to small cap and emerging growth companies recently issued a Buy Rating and a $7 Target Price for IntelliPharmaCeutics in anticipation of that first, key nod.

      What`s more, there could be several others right behind it.

      In the note to clients, the Brean analyst Jonathan Aschoff said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista`s potential market timing."

      The fact is, the relatively undiscovered Canadian firm now has six ANDAs being reviewed by the FDA for approval.

      Reported sales by others for branded and generic versions of the products in IPCI`s pipeline are approximately $6.6 billion. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway and if they manage to finally get the go ahead, the important endorsement for their drug platform could see shares appreciate significantly in the months and years ahead.

      Shameze Rampertab, CFO of Intellipharmaceutics: The Company is in discussions with the FDA on a regular and ongoing basis. We will only publicly announce updates if and when we are given final approval.

      Rampertab: IPCI believes that it could be accorded first-to-file status on one of the doses.

      Rampertab: IPCI is developing generics to drugs which are already in an extended-release or delayed-release format by the innovator pharmaceutical company. The drugs you have identified meet this criterion.

      Rampertab: The company is always open to considering licensing opportunities in order to maximize shareholder value. As we make additional progress with Phase I data we will initiate licensing discussions.

      Rampertab: We have already completed proof of concept for our abuse-deterrent oxycodone CR, and have disclosed these results. If successful, Phase I data will drive improved economics for licensing.

      Rampertab: In September, we announced the filing of two additional ANDAs with the FDA. In May we announced that we held a pre-IND meeting with the FDA to discuss our Rexista oxycodone development plan. Other short term goals that we hope to accomplish include, obtaining FDA approval of our generic version of Focalin XR, establishing additional development/marketing alliances, and completing the manufacture of clinical batches of Rexista oxycodone CR and initiating Phase I studies using those batches.

      GET READY FOR IPCI TO BREAK-OUT ANY DAY NOW------- ALSO: Brean Murray, Carret & Co.- the full-service, boutique investment bank dedicated to small cap and emerging growth companies recently issued a Buy Rating and a $7 Target Price for IPCI..

      Sentiment: Strong Buy

    • 1st of all ipci has the option to sell up to $25 million dollars worth of shares at $2.75 they already sold $5 million dollars worth 5 month ago...........if it is a ponzi scheme who gives $5 million dollars with out due diligence and they picked up the shares for $2.75 therefore the stock is worth no less then $2.75 also why would par pharma give ipci $$$$$$$$$$$$$ and enter into a partnership for the 1st fda approval............also if the stock is worthless like #$%$ al4g says then any dilution of ipci is what dilution of nothing is nothing.also note the ceo dr. Oddidi made bioval a billion dollar company before he left and it took them 7 years to get there 1st fda approval then the stock flew anybody with a $10,000 investment with bioval became a million dollar person.........so trash troll al4g lost all his families money with vasogan and has over 7000 bash posts on ipci he has no clue and is just a sore loser so all invested in ipci i will see you at the company party in toronto when this stock starts to take off and we are all worth a few million .

      Sentiment: Strong Buy

    • Brean Murray Carret & Co. initiates coverage on IntelliPharmaCeutics International (NASDAQ: IPCI) with a Buy. PT $7.00.

      Brean analyst said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista’s potential market timing."

      For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.

      Shares of IntelliPharmaCeutics International closed at $2.86 yesterday, with a 52 week range of $2.40-$3.82.

      Sentiment: Strong Buy

    • $$$$$$$$$$$$

      Sentiment: Strong Buy

    • $$$$$$$$$$$$$$$$$$$$$$$

      Sentiment: Strong Buy

    • View More Messages
 
IPCI
3.54-0.08(-2.21%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.